SCHEMBL30822383

SCHEMBL30822383

COc1ccc(C(=O)N2CCC(CC(=O)O)CC2)cc1N1CCC(=O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 2/20 0.44
▸ NR3C1 P04150 1/20 0.42
▸ PGR P06401 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ TNKS O95271 1/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ PARP10 Q53GL7 1/20 0.41
▸ TNKS2 Q9H2K2 1/20 0.41
▸ TLR8 Q9NR97 2/20 0.40
▸ TLR7 Q9NYK1 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29227486 1.00 FFAR4 (0.44) FFAR4NR3C1PGRSLC6A4KCNH2
SCHEMBL31255622 0.95 SOS1 (0.44) FFAR4NR3C1PGRSLC6A4KCNH2
SCHEMBL24735222 0.95 KDM4E (0.47) FFAR4NR3C1PGRSLC6A4KCNH2
SCHEMBL31586935 0.91 NR3C1 (0.41) NR3C1PGRSLC6A4KCNH2PDE3B
SCHEMBL25581203 0.90 NR3C1 (0.43) NR3C1PGRSLC6A4KCNH2PDE3B
SCHEMBL31586070 0.90 NR3C1 (0.43) NR3C1PGRSLC6A4KCNH2PDE3B
SCHEMBL29201735 0.90 NR3C1 (0.41) NR3C1PGRSLC6A4KCNH2PDE3B
SCHEMBL30864000 0.90 NR3C1 (0.41) NR3C1PGRSLC6A4KCNH2PDE3B
SCHEMBL29384475 0.90 NR3C1 (0.42) NR3C1PGRSLC6A4KCNH2PDE3B
SCHEMBL25221532 0.90 NR3C1 (0.42) NR3C1PGRSLC6A4KCNH2PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720044-A1 AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD Beactica Therapeutics AB (SE) 2026-04-08 — — EP disclosed
WO-2025103502-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN INC. (US) 2025-05-22 — — WO disclosed
US-20250082762-A1 NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-03-13 — — US disclosed
US-20250073341-A1 BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-03-06 — — US disclosed
US-12161722-B2 Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-12-10 — — US disclosed
WO-2024240840-A1 AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD BEACTICA THERAPEUTICS AB (SE) 2024-11-28 — — WO disclosed
US-20240285778-A1 NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-08-29 — — US disclosed
EP-4361153-A1 NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2024-05-01 — — EP disclosed
CN-117836299-A Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof 韩国化学研究院 2024-04-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250073341-A1 BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF BTK, XIAP, SYK FFAR4 4720/4885NR3C1 3432/4885PGR 2944/4885
US-20250082762-A1 NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF BTK, XIAP, UBE3C FFAR4 4715/4885NR3C1 3532/4885PGR 3117/4885
US-12161722-B2 Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof BTK, XIAP, SYK FFAR4 4720/4885NR3C1 3432/4885PGR 2944/4885
US-20240285778-A1 NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF BTK, XIAP, UBE3C FFAR4 4715/4885NR3C1 3532/4885PGR 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback